Dual-Tracer Imaging on a Long-Axial-Field-of-View PET: A Proof-of-Principle Study with [18F]FGln and [18F]FDG.
Daniel Kwon, Elizabeth J Li, Christina Dulal...
https://pubmed.ncbi.nlm.nih.gov/40506235/Actively Recruiting
Led by Abramson Cancer Center at Penn Medicine · Updated on 2026-01-22
40
Participants Needed
1
Research Sites
N/A
Total Duration
This research aims to evaluate the uptake of the imaging agent 18FF-GLN in patients with known or suspected primary or metastatic breast cancer who have at least one lesion 1.0 cm or larger. Up to 40 patients will participate, including at least 10 with estrogen-receptor-expressing breast cancer and 10 with triple-negative breast cancer. Participants may be new to treatment or have received up to three weeks of therapy at the time of the imaging scan. This is an observational study where imaging results do not guide treatment decisions, which remain based on clinical judgment. Participants will undergo approximately 60 minutes of dynamic PET scanning after injection of 18FF-GLN, followed by up to two static scans from skull base to mid-thigh. A baseline FDG-PETCT scan will also be performed, either as part of routine care or research. Some participants undergoing systemic therapy may have a second 18FF-GLN PETCT and possibly a second FDG-PETCT to explore changes in uptake related to treatment. Additional low-dose CT scans may be done if motion occurs during imaging. Throughout the study, metabolism data and image quality will be collected, along with preliminary information on 18FF-GLN uptake in breast cancer. Uptake will be compared to tumor markers of glutamine metabolism when tissue is available. Safety of 18FF-GLN will be monitored in all participants. The primary outcome is to assess the kinetics and biodistribution of 18FF-GLN, with secondary outcomes including safety, associations with tumor markers, metabolism, and changes after therapy, over a three-year period.
CONDITIONS
[18F] F-GLN by PET/CT in Breast Cancer
E
Erin Schubert
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Abramson Cancer Center at Penn Medicine
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | [18F]F‑GLN PET/CT (investigational) | Standard imaging pathways |
|---|---|---|
| What it is | An investigational molecular imaging method using fluoroglutamine labeled with 18F to evaluate uptake in breast cancer lesions. | Routine diagnostic imaging pathways that may include mammography, ultrasound, MRI, CT, or FDG‑PET/CT depending on clinical context. |
| Role in trial | Serves as the diagnostic test being investigated to assess lesion uptake. | Represents the comparator concept of how lesions are typically imaged in clinical care. |
| Primary use | To evaluate the kinetics and biodistribution of [18F]F‑GLN in primary and metastatic breast cancer lesions. | Used for detecting and characterizing breast lesions in routine clinical diagnosis and staging. |
| How it is performed | Single‑group PET/CT scan using an injected [18F]F‑GLN tracer to assess tumor uptake. | Imaging via standard modalities such as mammography, ultrasound, MRI, CT or FDG‑PET/CT as clinically appropriate. |
| Evidence status | Early–phase evidence evaluating imaging characteristics; diagnostic performance still under investigation. | Broadly validated for detection, staging, and characterization of breast lesions. |
| Important risks | Safety and tolerability are being monitored but not yet established. | Generally low‑risk, noninvasive imaging methods with well‑known safety profiles. |
| Important limitations | Results are limited to early‑phase assessment; clinical diagnostic accuracy relative to standard imaging not yet demonstrated. | Some lesions may be difficult to characterize depending on imaging modality; FDG‑PET/CT typically used only in staging, not initial detection. |
| Patient impact | Potential for improved lesion characterization with a novel tracer, but impact on care not yet established. | Current imaging supports diagnosis, staging, and treatment planning and is integrated into patient care. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 1 day
Participants undergo dynamic and static PET/CT scans with [18F]F-GLN and a baseline FDG-PET/CT scan to evaluate the uptake and distribution of the tracer in breast cancer lesions.
1 visit (in-person) for PET/CT imaging
Duration - Up to 3 years
Participants who receive systemic therapy as part of their clinical care may undergo optional second PET/CT scans to assess changes in [18F]F-GLN uptake in response to therapy over time.
Visits timing varies depending on treatment schedule; may include up to 2 additional PET/CT imaging visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Daniel Kwon, Elizabeth J Li, Christina Dulal...
https://pubmed.ncbi.nlm.nih.gov/40506235/Abramson Cancer Center at Penn Medicine
Lead Sponsor